sentence
stringlengths 27
1.01k
| drug1
stringlengths 2
46
| drug2
stringlengths 2
63
| relation
stringclasses 5
values | source_file
stringclasses 566
values | sentence_id
stringlengths 17
21
| pair_id
stringlengths 20
26
|
|---|---|---|---|---|---|---|
Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
|
primidone
|
rifampin
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s29
|
DDI-DrugBank.d64.s29.p267
|
When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
|
azithromycin
|
atorvastatin
|
MECHANISM
|
Azithromycin_ddi.xml
|
DDI-DrugBank.d53.s7
|
DDI-DrugBank.d53.s7.p0
|
Interactions for Vitamin B3 (Niacin): Antihypertensive Therapy: Nicotinic acid may potentiate the effects of ganglionic blocking agents and vasoactive drugs resulting in postural hypotension.
|
Nicotinic acid
|
ganglionic blocking agents
|
EFFECT
|
Niacin_ddi.xml
|
DDI-DrugBank.d542.s0
|
DDI-DrugBank.d542.s0.p9
|
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants
|
flupenthixol
|
Tricyclic antidepressants
|
NONE
|
Flupenthixol_ddi.xml
|
DDI-DrugBank.d13.s0
|
DDI-DrugBank.d13.s0.p44
|
Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.
|
NSAIDs
|
thiazides
|
EFFECT
|
Valdecoxib_ddi.xml
|
DDI-DrugBank.d328.s10
|
DDI-DrugBank.d328.s10.p4
|
Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males.
|
rifabutin
|
rifampin
|
NONE
|
11158747.xml
|
DDI-MedLine.d3.s0
|
DDI-MedLine.d3.s0.p2
|
We examined the effect of exogenous estradiol on the changes in serum steroid hormone levels induced by a nonlethal dose of Escherichia coli endotoxin in male rats and the deaths due to nonlethal and lethal doses of endotoxin.
|
estradiol
|
endotoxin
|
NONE
|
7600639.xml
|
DDI-MedLine.d39.s1
|
DDI-MedLine.d39.s1.p1
|
- Lithium: Lithium should generally not be given with diuretics (such as bumetanide) because they reduce its renal clearance and add a high risk of lithium toxicity.
|
Lithium
|
diuretics
|
ADVISE
|
Bumetanide_ddi.xml
|
DDI-DrugBank.d331.s3
|
DDI-DrugBank.d331.s3.p4
|
Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
|
Dexbrompheniramine
|
CNS depressants
|
EFFECT
|
Brompheniramine_ddi.xml
|
DDI-DrugBank.d192.s0
|
DDI-DrugBank.d192.s0.p1
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
antibiotics
|
quinidine
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p344
|
Standard monitoring of methotrexate-related toxicity should be continued if VIOXX and methotrexate are administered concomitantly.
|
VIOXX
|
methotrexate
|
ADVISE
|
Rofecoxib_ddi.xml
|
DDI-DrugBank.d210.s22
|
DDI-DrugBank.d210.s22.p2
|
Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, anesthetics) should be considered.
|
IOPIDINE
|
alcohol
|
ADVISE
|
Apraclonidine_ddi.xml
|
DDI-DrugBank.d224.s1
|
DDI-DrugBank.d224.s1.p1
|
Insulin or Oral Hypoglycemics: Agents with b-blocking properties may enhance the blood-sugar-reducing effect of insulin and oral hypoglycemics.
|
Agents with b-blocking properties
|
insulin
|
EFFECT
|
Carvedilol_ddi.xml
|
DDI-DrugBank.d269.s18
|
DDI-DrugBank.d269.s18.p7
|
Concomitant administration of naproxen and aspirin is not recommended because naproxen is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations and peak plasma levels.
|
naproxen
|
aspirin
|
ADVISE
|
Naproxen_ddi.xml
|
DDI-DrugBank.d85.s6
|
DDI-DrugBank.d85.s6.p0
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
anabolic steroids
|
prolonged narcotics
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p294
|
Increased nephrotoxicity has been reported following concomitant administration of cephalosporins and aminoglycoside antibiotics.
|
cephalosporins
|
aminoglycoside antibiotics
|
EFFECT
|
Cefoxitin_ddi.xml
|
DDI-DrugBank.d556.s0
|
DDI-DrugBank.d556.s0.p0
|
Potential drug interactions between Keppra and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.
|
Keppra
|
primidone
|
NONE
|
Levetiracetam_ddi.xml
|
DDI-DrugBank.d212.s11
|
DDI-DrugBank.d212.s11.p6
|
Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
|
5-fluorouracil
|
methadone
|
NONE
|
Levothyroxine_ddi.xml
|
DDI-DrugBank.d411.s3
|
DDI-DrugBank.d411.s3.p102
|
No significant drug interactions have been reported in studies of candesartan cilexetil given with other drugs such as glyburide, nifedipine, digoxin, warfarin, hydrochlorothiazide, and oral contraceptives in healthy volunteers, or given with enalapril to patients with heart failure (NYHA class II and III).
|
digoxin
|
enalapril
|
NONE
|
Candesartan_ddi.xml
|
DDI-DrugBank.d547.s0
|
DDI-DrugBank.d547.s0.p21
|
Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).
|
Zarontin
|
antiepileptic drugs
|
INT
|
Ethosuximide_ddi.xml
|
DDI-DrugBank.d205.s0
|
DDI-DrugBank.d205.s0.p1
|
Plasma concentrations of cyclosporine should therefore be closely monitored, and its dosage reduced accordingly, in patients treated with nicardipine.
|
cyclosporine
|
nicardipine
|
ADVISE
|
Nicardipine_ddi.xml
|
DDI-DrugBank.d468.s9
|
DDI-DrugBank.d468.s9.p0
|
Compounds tested in man include warfarin, theophylline, phenytoin, diazepam, aminopyrine and antipyrine.
|
warfarin
|
theophylline
|
NONE
|
Famotidine_ddi.xml
|
DDI-DrugBank.d203.s2
|
DDI-DrugBank.d203.s2.p0
|
The concurrent administration of allopurinol and ampicillin increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving ampicillin alone.
|
allopurinol
|
ampicillin
|
EFFECT
|
Clavulanate_ddi.xml
|
DDI-DrugBank.d419.s0
|
DDI-DrugBank.d419.s0.p0
|
Aspirin: Concurrent administration of aspirin may lower meclofenamate sodium plasma levels, possibly by competing for protein-binding sites.
|
aspirin
|
meclofenamate sodium
|
MECHANISM
|
Meclofenamic acid_ddi.xml
|
DDI-DrugBank.d113.s2
|
DDI-DrugBank.d113.s2.p2
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
EQUETROTM
|
bupropion
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p3
|
Bosentan is also expected to reduce plasma concentrations of other oral hypoglycemic agents that are predominantly metabolized by CYP2C9 or CYP3A4.
|
Bosentan
|
hypoglycemic agents
|
MECHANISM
|
Bosentan_ddi.xml
|
DDI-DrugBank.d289.s21
|
DDI-DrugBank.d289.s21.p0
|
Central Nervous System Depressants: The concomitant use of DURAGESIC (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
|
DURAGESIC
|
opioids
|
EFFECT
|
Fentanyl_ddi.xml
|
DDI-DrugBank.d170.s5
|
DDI-DrugBank.d170.s5.p14
|
Organic nitrates - L-arginine supplements theoretically may potentiate the effects of organic nitrates if taken concomitantly.
|
L-arginine
|
nitrates
|
EFFECT
|
L-Arginine_ddi.xml
|
DDI-DrugBank.d95.s2
|
DDI-DrugBank.d95.s2.p2
|
When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
|
efavirenz
|
midazolam
|
NONE
|
Azithromycin_ddi.xml
|
DDI-DrugBank.d53.s7
|
DDI-DrugBank.d53.s7.p67
|
Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.
|
Quinolone Antibiotic
|
ciprofloxacin
|
NONE
|
Didanosine_ddi.xml
|
DDI-DrugBank.d43.s8
|
DDI-DrugBank.d43.s8.p2
|
Quinolones, including cinoxacin, may enhance the effects of oral anticoagulants, such as warfarin or its derivatives.
|
Quinolones
|
warfarin
|
EFFECT
|
Cinoxacin_ddi.xml
|
DDI-DrugBank.d562.s8
|
DDI-DrugBank.d562.s8.p2
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
oxolinic acid
|
tolbutamide
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p1290
|
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.
|
anticonvulsants
|
benzodiazepines
|
NONE
|
Finasteride_ddi.xml
|
DDI-DrugBank.d209.s3
|
DDI-DrugBank.d209.s3.p65
|
The concomitant administration of rifampin and warfarin resulted in the need for an unusually high maintenance dose of warfarin (20 mg per day) in order to produce a therapeutic effect.
|
rifampin
|
warfarin
|
MECHANISM
|
1115445.xml
|
DDI-MedLine.d116.s3
|
DDI-MedLine.d116.s3.p0
|
Because dopamine is metabolized by monoamine oxidase (MAO), inhibition of this enzyme prolongs and potentiates the effect of dopamine.
|
dopamine
|
dopamine
|
NONE
|
Dopamine_ddi.xml
|
DDI-DrugBank.d325.s0
|
DDI-DrugBank.d325.s0.p0
|
Products containing calcium and other multivalent cations likely will interfere with absorption of alendronate.
|
calcium
|
alendronate
|
MECHANISM
|
Alendronate_ddi.xml
|
DDI-DrugBank.d430.s3
|
DDI-DrugBank.d430.s3.p1
|
Concomitant administration of probenecid doubled the AUC for cefprozil.
|
probenecid
|
cefprozil
|
MECHANISM
|
Cefprozil_ddi.xml
|
DDI-DrugBank.d121.s1
|
DDI-DrugBank.d121.s1.p0
|
No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.
|
hydrochlorothiazide
|
nifedipine
|
NONE
|
Irbesartan_ddi.xml
|
DDI-DrugBank.d27.s0
|
DDI-DrugBank.d27.s0.p2
|
Since bacteriostatic drugs, such as the tetracycline class of antibiotics, may interfere with the bactericidal action of penicillins, it is not advisable to administer these drugs concomitantly.
|
tetracycline class
|
penicillins
|
EFFECT
|
Demeclocycline_ddi.xml
|
DDI-DrugBank.d409.s1
|
DDI-DrugBank.d409.s1.p1
|
These pharmacokinetic effects seen during diltiazem coadministration can result in increased clinical effects (e.g., prolonged sodation)of both midazolam and triazolam.
|
diltiazem
|
midazolam
|
EFFECT
|
Diltiazem_ddi.xml
|
DDI-DrugBank.d565.s35
|
DDI-DrugBank.d565.s35.p0
|
While all the selective serotonin reuptake inhibitors (SSRIs), e. g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.
|
selective serotonin reuptake inhibitors
|
sertraline
|
NONE
|
Imipramine_ddi.xml
|
DDI-DrugBank.d77.s15
|
DDI-DrugBank.d77.s15.p2
|
Potential drug interactions between Keppra and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.
|
Keppra
|
gabapentin
|
NONE
|
Levetiracetam_ddi.xml
|
DDI-DrugBank.d212.s11
|
DDI-DrugBank.d212.s11.p2
|
Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.
|
acetaminophen
|
anesthetics
|
EFFECT
|
Butalbital_ddi.xml
|
DDI-DrugBank.d559.s1
|
DDI-DrugBank.d559.s1.p12
|
Warfarin: When fluvoxamine maleate (50 mg tid) was administered concomitantly with warfarin for two weeks, warfarin plasma concentrations increased by 98% and prothrombin times were prolonged.
|
fluvoxamine maleate
|
warfarin
|
MECHANISM
|
Fluvoxamine_ddi.xml
|
DDI-DrugBank.d76.s30
|
DDI-DrugBank.d76.s30.p3
|
Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.
|
indomethacin
|
alprazolam
|
NONE
|
Digoxin_ddi.xml
|
DDI-DrugBank.d450.s2
|
DDI-DrugBank.d450.s2.p31
|
Morphine: Combination hormonal contraceptives may increase the clearance of morphine.
|
Morphine
|
hormonal contraceptives
|
NONE
|
Ethynodiol Diacetate_ddi.xml
|
DDI-DrugBank.d485.s26
|
DDI-DrugBank.d485.s26.p0
|
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.
|
cyclophosphamide
|
bleomycin
|
NONE
|
11148572.xml
|
DDI-MedLine.d115.s2
|
DDI-MedLine.d115.s2.p38
|
Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.
|
Quinolone Antibiotic
|
aluminum
|
NONE
|
Didanosine_ddi.xml
|
DDI-DrugBank.d43.s8
|
DDI-DrugBank.d43.s8.p6
|
Patients treated with proton pump inhibitors and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.
|
proton pump inhibitors
|
warfarin
|
EFFECT
|
Esomeprazole_ddi.xml
|
DDI-DrugBank.d29.s6
|
DDI-DrugBank.d29.s6.p0
|
Corticosteroids and Corticotropin (ACTH): may potentiate amphotericin B- induced hypokalemia which may predispose the patient to cardiac dysfunction.
|
Corticotropin
|
amphotericin B
|
EFFECT
|
Amphotericin B_ddi.xml
|
DDI-DrugBank.d318.s2
|
DDI-DrugBank.d318.s2.p4
|
Use in Conjunction with Other Antiepileptic Drugs: The addition of Felbatol to antiepileptic drugs (AEDs) affects the steady-state plasma concentrations of AEDs.
|
Felbatol
|
antiepileptic drugs
|
MECHANISM
|
Felbamate_ddi.xml
|
DDI-DrugBank.d434.s1
|
DDI-DrugBank.d434.s1.p4
|
Betaseron administration to three cancer patients over a dose range of 0.025 mg to 2.2 mg led to a dose-dependent inhibition of antipyrine elimination.14 The effect of alternate-day administration of 0.25 mg of Betaseron on drug metabolism in MS patients is unknown.
|
Betaseron
|
antipyrine
|
MECHANISM
|
Interferon beta-1b_ddi.xml
|
DDI-DrugBank.d10.s2
|
DDI-DrugBank.d10.s2.p0
|
Probenecid: As with other b-lactam antibiotics, probenecid inhibits the renal excretion of cefdinir, resulting in an approximate doubling in A.C. a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination half-life.
|
b-lactam antibiotics
|
probenecid
|
NONE
|
Cefdinir_ddi.xml
|
DDI-DrugBank.d420.s4
|
DDI-DrugBank.d420.s4.p4
|
A pharmacokinetic study evaluating the administration of a single dose of INSPRA 100 mg with ketoconazole 200 mg BID, a potent inhibitor of the CYP3A4 pathway, showed a 1.7-fold increase in Cmax of eplerenone and a 5.4-fold increase in AUC of eplerenone.
|
INSPRA
|
eplerenone
|
NONE
|
Eplerenone_ddi.xml
|
DDI-DrugBank.d20.s1
|
DDI-DrugBank.d20.s1.p2
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
dextrothyroxine
|
phenytoin
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p728
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
protease inhibitors
|
quetiapine
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p969
|
Caffeine administered concurrently with ketoprofen reduced the urine volume in 4 healthy volunteers.
|
Caffeine
|
ketoprofen
|
EFFECT
|
Caffeine_ddi.xml
|
DDI-DrugBank.d89.s4
|
DDI-DrugBank.d89.s4.p0
|
Amantadine, tricyclic antidepressants, and MAOIs may increase anticholinergic effect of clidinium.
|
Amantadine
|
clidinium
|
EFFECT
|
Clidinium_ddi.xml
|
DDI-DrugBank.d322.s0
|
DDI-DrugBank.d322.s0.p2
|
Phenytoin, nicotine, and rifampin may decrease Clozapine plasma levels, resulting in a decrease in effectiveness of a previously effective Clozapine dose.
|
rifampin
|
Clozapine
|
MECHANISM
|
Clozapine_ddi.xml
|
DDI-DrugBank.d480.s15
|
DDI-DrugBank.d480.s15.p7
|
Propoxyphene: In cases of propoxyphene overdosage, amphetamine CNS stimulation is potentiated and fatal convulsions can occur.
|
propoxyphene
|
amphetamine
|
EFFECT
|
Lisdexamfetamine_ddi.xml
|
DDI-DrugBank.d158.s23
|
DDI-DrugBank.d158.s23.p2
|
MAO inhibitors MAOI antidepressants, as well as a metabolite of furazolidone, slow amphetamine metabolism.
|
MAOI antidepressants
|
amphetamine
|
MECHANISM
|
Lisdexamfetamine_ddi.xml
|
DDI-DrugBank.d158.s6
|
DDI-DrugBank.d158.s6.p4
|
Some reports have shown that the concomitant administration of thiazides with vitamin D causes hypercalcemia.
|
thiazides
|
vitamin D
|
EFFECT
|
Calcidiol_ddi.xml
|
DDI-DrugBank.d98.s5
|
DDI-DrugBank.d98.s5.p0
|
BROVANA, as with other beta2-agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval because the action of adrenergic agonists on the cardiovascular system may be potentiated by these agents.
|
BROVANA
|
monoamine oxidase inhibitors
|
ADVISE
|
Arformoterol_ddi.xml
|
DDI-DrugBank.d284.s6
|
DDI-DrugBank.d284.s6.p1
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Neoral
|
Prelone
|
NONE
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p752
|
- Probenecid: Pretreatment with probenecid reduces both the natriuresis and hyperreninemia produced by bumetanide.
|
probenecid
|
bumetanide
|
EFFECT
|
Bumetanide_ddi.xml
|
DDI-DrugBank.d331.s4
|
DDI-DrugBank.d331.s4.p2
|
- Drugs that may decrease plasma phenytoin concentrations include: carbamazepine, chronic alcohol abuse, reserpine
|
phenytoin
|
alcohol
|
MECHANISM
|
Fosphenytoin_ddi.xml
|
DDI-DrugBank.d40.s12
|
DDI-DrugBank.d40.s12.p1
|
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
|
NIMBEX
|
colistin
|
EFFECT
|
Cisatracurium Besylate_ddi.xml
|
DDI-DrugBank.d60.s12
|
DDI-DrugBank.d60.s12.p22
|
Extended Release Tablets: Administration of nifedipine with digoxin increased digoxin levels in 9 of 12 normal volunteers.
|
digoxin
|
digoxin
|
MECHANISM
|
Nifedipine_ddi.xml
|
DDI-DrugBank.d373.s3
|
DDI-DrugBank.d373.s3.p2
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
chymotrypsin
|
phenylbutazone
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p521
|
Prolonged recovery time may occur if barbiturates and/or narcotics are used concurrently with ketamine.
|
narcotics
|
ketamine
|
EFFECT
|
Ketamine_ddi.xml
|
DDI-DrugBank.d518.s0
|
DDI-DrugBank.d518.s0.p2
|
The concurrent use of intravenously or orally administered methylxanthines (e.g., aminophylline, theophylline) by patients receiving BROVANA has not been completely evaluated.
|
methylxanthines
|
aminophylline
|
NONE
|
Arformoterol_ddi.xml
|
DDI-DrugBank.d284.s8
|
DDI-DrugBank.d284.s8.p0
|
Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.
|
aluminum
|
FACTIVE
|
ADVISE
|
Gemifloxacin_ddi.xml
|
DDI-DrugBank.d347.s7
|
DDI-DrugBank.d347.s7.p16
|
Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin.
|
dexamethasone
|
EGF
|
EFFECT
|
3881461.xml
|
DDI-MedLine.d12.s2
|
DDI-MedLine.d12.s2.p2
|
Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.
|
antacids
|
calcium
|
NONE
|
Didanosine_ddi.xml
|
DDI-DrugBank.d43.s8
|
DDI-DrugBank.d43.s8.p23
|
Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
|
adrenocortical steroids
|
glutethimide
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s29
|
DDI-DrugBank.d64.s29.p34
|
For example, since cholestyramine may reduce the gastrointestinal absorption of both the oral anticoagulants and vitamin K, the net effects are unpredictable.
|
cholestyramine
|
anticoagulants
|
MECHANISM
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s3
|
DDI-DrugBank.d64.s3.p0
|
It is recommended that gabapentin be taken at least 2 hours following Maalox administration.
|
gabapentin
|
Maalox
|
ADVISE
|
Gabapentin_ddi.xml
|
DDI-DrugBank.d438.s39
|
DDI-DrugBank.d438.s39.p0
|
The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin.
|
sodium carboxymethylcellulose
|
bacitracin
|
NONE
|
11154900.xml
|
DDI-MedLine.d76.s1
|
DDI-MedLine.d76.s1.p5
|
Terfenadine: No clinically significant changes occurred in heart rate or corrected QT intervals, or in terfenadine metabolite or lomefloxacin pharmacokinetics, during concurrent administration of lomefloxacin and terfenadine at steady-state in 28 healthy males.
|
terfenadine
|
lomefloxacin
|
NONE
|
Lomefloxacin_ddi.xml
|
DDI-DrugBank.d516.s23
|
DDI-DrugBank.d516.s23.p5
|
- Cholestyramine and colestipol resins: Cholestytamine and colestipol resins have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract
|
Cholestytamine
|
thiazide diuretics
|
MECHANISM
|
Chlorothiazide_ddi.xml
|
DDI-DrugBank.d46.s7
|
DDI-DrugBank.d46.s7.p20
|
The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant.
|
benzodiazepines
|
triazolam
|
NONE
|
Aprepitant_ddi.xml
|
DDI-DrugBank.d382.s23
|
DDI-DrugBank.d382.s23.p5
|
Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;
|
Cholestyramine
|
fat soluble vitamins
|
MECHANISM
|
Cholecalciferol_ddi.xml
|
DDI-DrugBank.d404.s0
|
DDI-DrugBank.d404.s0.p27
|
ERGAMISOL (levamisole hydrochloride) has been reported to produce ANTABUSE-like side effects when given concomitantly with alcohol.
|
ERGAMISOL
|
alcohol
|
EFFECT
|
Levamisole_ddi.xml
|
DDI-DrugBank.d381.s0
|
DDI-DrugBank.d381.s0.p1
|
However, concomitant administration of aspirin with CELEBREX may result in an increased rate of GI ulceration or other complications, compared to use of CELEBREX alone.
|
aspirin
|
CELEBREX
|
NONE
|
Celecoxib_ddi.xml
|
DDI-DrugBank.d172.s14
|
DDI-DrugBank.d172.s14.p1
|
Caffeine-related adverse effects have occurred in patients consuming caffeine while on therapy with enoxacin.
|
Caffeine
|
enoxacin
|
NONE
|
Enoxacin_ddi.xml
|
DDI-DrugBank.d395.s5
|
DDI-DrugBank.d395.s5.p1
|
Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.
|
quinidine
|
aripiprazole
|
MECHANISM
|
Aripiprazole_ddi.xml
|
DDI-DrugBank.d509.s8
|
DDI-DrugBank.d509.s8.p6
|
In addition, deaths have been reported rarely with concomitant administration of terfenadine and erythromycin.
|
terfenadine
|
erythromycin
|
EFFECT
|
Erythromycin_ddi.xml
|
DDI-DrugBank.d397.s12
|
DDI-DrugBank.d397.s12.p0
|
In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.
|
monoamine oxidase inhibitors
|
serotoninergic agents
|
EFFECT
|
Dexfenfluramine_ddi.xml
|
DDI-DrugBank.d423.s0
|
DDI-DrugBank.d423.s0.p2
|
In some patients, the administration of INDOCIN can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing, and thiazide diuretics.
|
INDOCIN
|
loop diuretics
|
EFFECT
|
Indomethacin_ddi.xml
|
DDI-DrugBank.d82.s23
|
DDI-DrugBank.d82.s23.p0
|
H1 and H2 Blockers - Although not reported, L-histidine, via its metabolism to histamine, might decrease the efficacy of H1 and H2 blockers.
|
L-histidine
|
H2 blockers
|
EFFECT
|
L-Histidine_ddi.xml
|
DDI-DrugBank.d365.s1
|
DDI-DrugBank.d365.s1.p8
|
Concomitant use of antihistamines with alcohol, tricyclic antidepressants, barbiturates, or other central nervous system depressants may have an additive effect.
|
antihistamines
|
barbiturates
|
EFFECT
|
Azatadine_ddi.xml
|
DDI-DrugBank.d448.s1
|
DDI-DrugBank.d448.s1.p2
|
Theophylline: A single 10 mg dose of tiagabine did not affect the pharmacokinetics of theophylline at steady state.
|
tiagabine
|
theophylline
|
NONE
|
Tiagabine_ddi.xml
|
DDI-DrugBank.d277.s16
|
DDI-DrugBank.d277.s16.p2
|
Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
|
acetaminophen
|
procainamide
|
NONE
|
Bentiromide_ddi.xml
|
DDI-DrugBank.d537.s0
|
DDI-DrugBank.d537.s0.p23
|
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
|
estrogens
|
progestogens
|
NONE
|
Insulin recombinant_ddi.xml
|
DDI-DrugBank.d313.s2
|
DDI-DrugBank.d313.s2.p102
|
TAMBOCOR has been administered to patients receiving digitalis preparations or beta-adrenergic blocking agents without adverse effects.
|
digitalis preparations
|
beta-adrenergic blocking agents
|
NONE
|
Flecainide_ddi.xml
|
DDI-DrugBank.d87.s1
|
DDI-DrugBank.d87.s1.p2
|
Effects of Other Antiepileptic Drugs on Felbatol Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol as compared to the same dose of Felbatol given as monotherapy.
|
Felbatol
|
Felbatol
|
NONE
|
Felbamate_ddi.xml
|
DDI-DrugBank.d434.s30
|
DDI-DrugBank.d434.s30.p28
|
The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decrease by concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and adjustment of the dosage of imipramine may therefore be necessary.
|
imipramine
|
cimetidine
|
MECHANISM
|
Imipramine_ddi.xml
|
DDI-DrugBank.d77.s5
|
DDI-DrugBank.d77.s5.p0
|
MAO inhibitors: MAOI antidepressants, as well as a metabolite of furazolidone, slow amphetamine metabolism.
|
MAOI antidepressants
|
amphetamine
|
MECHANISM
|
Dextroamphetamine_ddi.xml
|
DDI-DrugBank.d236.s10
|
DDI-DrugBank.d236.s10.p4
|
Co-administration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.
|
atenolol
|
hydrochlorothiazide
|
NONE
|
Aliskiren_ddi.xml
|
DDI-DrugBank.d533.s1
|
DDI-DrugBank.d533.s1.p15
|
Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.
|
Opioids
|
anesthetics
|
NONE
|
Dexmedetomidine_ddi.xml
|
DDI-DrugBank.d197.s1
|
DDI-DrugBank.d197.s1.p22
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.